ClinicalTrials.gg
CompletedNCT05148351Updated Oct 24, 2022

Validity of an App to Detect Frailty and Sarcopenia Syndromes in Elderly

An observational study in Sarcopenia, Frailty Syndrome and Aging, sponsored by Catholic University of Murcia. Completed at 1 site in Spain. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Catholic University of Murcia · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
775
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.

Enrollment
Largest of 22
775 · median 156
Started
2022
with 14 others
Observational
22 of 99
7 open now
Registered
35th of 99
by date

Among the 99 studies in Sarcopenia with a site in Spain, this one has the largest enrollment of the 22 observational ones that give a count, is one of 15 that started in 2022, is one of 22 observational ones, and was the 35th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Sarcopenia with a site in Spain, or all of them as a file.
02

Study summary

Frailty and sarcopenia are two age-related syndromes which can result in adverse health-related events. The combination of both is more predictive of mortality than either condition alone. These conditions can be reversed through an early detection and appropriate interventions. Nevertheless, scientific community highlights the lack of cheap, portable, rapid and easy-to-use tools for detecting frailty and sarcopenia in combination. The aim of this study is to validate an iPhone App to detect frailty and sarcopenia syndromes in community dwelling older adults. This is a protocol study of a retrospective diagnostic test accuracy study which will include at least 400 participants older than 60 years recruited from elderly social centers of Murcia city. Researchers will recollect data of health status, dependency, cognitive status, and functional capacity of the participants. The index test will consist in the measurement of muscle power exerted during a single Sit-to-stand through an App (iPhone), combined with calf and mid-upper arm circumference. The reference standard will be frailty syndrome and sarcopenia assessed according to Fried's phenotype and to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019) recommendations, respectively. Sensitivity, specificity, positive predictive value, negative predictive values, and area under the curve will be reported.

03

Conditions studied

  • Sarcopenia
  • Frailty Syndrome
  • Aging
  • Aged
  • Diagnosis

Keywords

  • Functional Capacity
  • Sit-to-Stand Test
  • Muscle Power
  • Chair rise
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

At least 400 community-dwelling older adults, older than 60 y/o and living in the Region of Murcia (Spain) will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Community-dwelling older adults living in the Region of Murcia

Exclusion criteria

Exclusion Criteria:

  • Barthel Index \< 90 pts.
  • Mini-Cog test \< 3 pts.
  • Severe cardiovascular problems
  • Pacemaker
  • Automatic defibrillator
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
775 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Muscular power

    Muscular power generated by participants will be measured using an App (Sit-to-stand App version 1.1) installed on an iPhone (Apple Inc., USA). During the execution, subjects will sit on a rigid chair with their arms crossed over their chest with the hip, knee and ankle joints at approximately 90 degrees. Subjects will be asked to stand-up as fast as possible. Participants will complete three STS repetitions. No footwear will be allowed during the test.

    Time frame: Cross-sectional baseline

  2. Frailty Syndrome

    Frailty Syndrome will be assessed according to Fried's Phenotype, which focuses on: 1. Handgrip strength 2. Usual gait speed 3. Weight loss 4. Exhaustion 5. Physical activity levels Subjects who will result positive to three out of five criteria will be considered as "frail", whereas if they will result positive to only one or two of them they will be considered as "pre-frail". The absence of each criteria will be necessary to define a subject as "robust".

    Time frame: Cross-sectional baseline

  3. Sarcopenia

    Sarcopenia will be assessed according to the recommendation provided by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) (2019). This guideline focuses on the assessment of: 1. Leg muscle strength 2. Muscle mass quantity 3. Physical performance The presence of low muscle strength levels will be considered as "probable sarcopenia"; the presence of low muscle mass and strength levels will be considered as "confirmed sarcopenia"; finally, the presence of the three criteria will be considered as "severe sarcopenia".

    Time frame: Cross-sectional baseline

  4. Calf and mid-upper arm circumference

    Researchers will measure subjects' calf and mid-upper arm circumference using a tape measure.

    Time frame: Cross-sectional baseline

Secondary outcomes

  1. Subjects' clinical status

    Subjects' clinical status will be assessed through a list of questions regarding: * socioeconomic level * educational level * chronic pathologies * smoking habits * polypharmacy * depression * number of falls * hospitalization * self-perceived health status

    Time frame: Cross-sectional baseline

07

Study locations

1 site
  • Catholic University of Murcia
    Murcia, 30107, Spain
08

References and documents

Publications

  • Montemurro A, Ruiz-Cardenas JD, Martinez-Garcia MDM, Rodriguez-Juan JJ. Validity of an iPhone App to Detect Prefrailty and Sarcopenia Syndromes in Community-Dwelling Older Adults: The Protocol for a Diagnostic Accuracy Study. Sensors (Basel). 2022 Aug 11;22(16):6010. doi: 10.3390/s22166010. PubMed 36015771 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Oct 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2021
First posted
Dec 8, 2021
StartActual
Feb 17, 2022
Primary completionActual
Oct 1, 2022
CompletionActual
Oct 1, 2022
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05148351
Lead sponsor
Catholic University of Murcia
Responsible party
Alessio Montemurro (Principal Investigator, Catholic University of Murcia) — Principal investigator
First posted
Dec 8, 2021
Start date
Feb 17, 2022
Primary completion
Oct 1, 2022
Completion
Oct 1, 2022
Last update
Oct 24, 2022

Study contacts

Juan D Ruiz-Cárdenas
study director · Catholic University of Murcia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion